Amgen has licensed ImmunoGen's Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics for an undisclosed amount.
ImmunoGen president and CEO Daniel Junius said major healthcare companies are interested in developing multiple product candidates with TAP technology.
"In recent years, there has been a marked increase in the quantity of targets considered to be potentially appropriate for TAP compounds, which has expanded the opportunity for us and our partners," Junius added.
ImmunoGen, as part of license agreement signed in 2000, will receive a $1m upfront payment and is eligible to receive milestone payments worth $34m as well as royalties on the sales of resulting products while Amgen will develop, manufacture and market products resulting from the license.
In 2009, Amgen had also licensed TAP technology for two other targets and also has two compounds in clinical testing under the same licenses.
